IL85961A - Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor - Google Patents

Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor

Info

Publication number
IL85961A
IL85961A IL85961A IL8596188A IL85961A IL 85961 A IL85961 A IL 85961A IL 85961 A IL85961 A IL 85961A IL 8596188 A IL8596188 A IL 8596188A IL 85961 A IL85961 A IL 85961A
Authority
IL
Israel
Prior art keywords
dna
factor
leukemia
encodes
purification
Prior art date
Application number
IL85961A
Other languages
English (en)
Original Assignee
Amrad Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Corp Ltd filed Critical Amrad Corp Ltd
Publication of IL85961A publication Critical patent/IL85961A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL85961A 1987-04-02 1988-04-01 Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor IL85961A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPI120987 1987-04-02
AUPI331787 1987-07-24
AUPI490387 1987-10-15
AUPI600587 1987-12-21

Publications (1)

Publication Number Publication Date
IL85961A true IL85961A (en) 1997-03-18

Family

ID=27424196

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85961A IL85961A (en) 1987-04-02 1988-04-01 Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor

Country Status (15)

Country Link
US (5) US5187077A (da)
EP (1) EP0285448B1 (da)
JP (2) JP2682858B2 (da)
KR (1) KR0121324B1 (da)
CA (1) CA1341581C (da)
DE (1) DE3888379T2 (da)
DK (1) DK174970B1 (da)
ES (1) ES2061643T3 (da)
FI (1) FI113372B (da)
HK (1) HK33695A (da)
IL (1) IL85961A (da)
NO (1) NO178265C (da)
PT (1) PT87133B (da)
SG (1) SG11795G (da)
WO (1) WO1988007548A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
DE68928914T2 (de) * 1988-08-04 1999-09-09 Amrad Corp. Ltd. (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
US20030032178A1 (en) * 1988-08-04 2003-02-13 Williams Robert Lindsay In vitro propagation of embryonic stem cells
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
AU5104390A (en) * 1989-02-08 1990-09-05 Uab Research Foundation Antiproliferation factor
ATE138267T1 (de) * 1989-11-24 1996-06-15 Univ Monash Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen
DE69119759T2 (de) * 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
WO1993012806A1 (en) * 1991-12-24 1993-07-08 Amrad Corporation Limited A method for the treatment of tumours and sarcomas
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
CA2139504A1 (en) * 1992-07-01 1994-01-20 Nicos A. Nicola Leukaemia inhibitory factor-binding protein
EP0746569A4 (en) * 1993-02-03 1999-03-24 Amrad Corp Ltd DETERMINANT FOR FIXING THE RECEPTOR FROM THE LEUKEMIA INHIBITION FACTOR
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
WO1995020661A1 (en) * 1994-01-27 1995-08-03 Bresatec Ltd. Materials and methods for management of hyperacute rejection in human xenotransplantation
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
US6184370B1 (en) * 1994-02-03 2001-02-06 Amrad Corporation Limited Receptor-binding determinant from leukaemia inhibitory factor
US5824838A (en) * 1996-05-09 1998-10-20 Cedars-Sinai Medical Center Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
WO1998004587A1 (en) * 1996-07-25 1998-02-05 New York University POLYPEPTIDE COFACTORS THAT MEDIATE α-TUBULIN AND β-TUBULIN FOLDING
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
AUPP053197A0 (en) 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
AU753197B2 (en) 1998-07-06 2002-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for in vitro fertilization
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
JP2004503256A (ja) * 2000-06-14 2004-02-05 ビスタジェン　インコーポレイテッド 肝臓幹細胞を使用する毒性分類
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7604807B2 (en) * 2000-12-01 2009-10-20 Auburn University Use of pullulan to isolate and preserve biological material
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
US20030211605A1 (en) * 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
EP1435779A4 (en) * 2001-09-24 2005-06-01 Sangamo Biosciences Inc MODULATION OF STEM CELLS USING ZINC FINGER PROTEINS (ZFP)
GB0220145D0 (en) * 2002-08-30 2002-10-09 Thromb X Nv Novel compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability
EP1458852B1 (en) 2001-12-21 2011-03-09 ThromboGenics N.V. Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2004112661A1 (en) * 2003-06-20 2004-12-29 Myers Thomas H Method and apparatus for strengthening the biomechanical properties of implants
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
FR2870854B1 (fr) * 2004-05-26 2010-12-31 Oreal Utilisation du lif en ingenierie cellulaire et tissulaire
US20050277124A1 (en) 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
MX2008016429A (es) * 2006-06-20 2009-03-20 Genzyme Corp Medios de suero y sus usos para expansion de condrocitos.
JPWO2011125948A1 (ja) 2010-04-02 2013-07-11 独立行政法人理化学研究所 Ｅｓ細胞の製造方法
KR101434739B1 (ko) * 2012-08-23 2014-09-01 울산대학교 산학협력단 인간 ＰＤＩｂ´ａ´태그를 이용한 생물학적 활성을 가진 인간 ＬＩＦ 재조합 단백질의 대장균 내 발현 및 정제방법
EP3561050B1 (en) 2013-02-20 2021-12-08 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
WO2019169371A1 (en) * 2018-03-02 2019-09-06 University Of Florida Research Foundation, Incorporated Drug stabilized therapeutic transgenes delivered by adeno-associated virus expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578355A (en) * 1983-01-12 1986-03-25 The United States Of America As Represented By The Department Of Health And Human Services Plasmid cloning vector pAS1
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
US4616079A (en) * 1984-08-24 1986-10-07 Imreg, Inc. Immunoamplifiers and processes for the extraction thereof
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
JPS62223126A (ja) * 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
JPS6448197A (en) * 1987-08-19 1989-02-22 Sanden Corp Goods takeoff port unit for vending machine
JPH01148197A (ja) * 1987-12-04 1989-06-09 Green Cross Corp:The 腫瘍細胞障害因子

Also Published As

Publication number Publication date
JPH07138292A (ja) 1995-05-30
EP0285448B1 (en) 1994-03-16
NO885339D0 (no) 1988-11-30
US5443825A (en) 1995-08-22
DK174970B1 (da) 2004-04-05
KR0121324B1 (ko) 1997-11-28
PT87133B (pt) 1992-07-31
EP0285448A2 (en) 1988-10-05
NO885339L (no) 1989-02-01
PT87133A (pt) 1988-04-01
DE3888379D1 (de) 1994-04-21
FI113372B (fi) 2004-04-15
JPH01502985A (ja) 1989-10-12
US5427925A (en) 1995-06-27
KR890700610A (ko) 1989-04-26
HK33695A (en) 1995-03-17
JP2682858B2 (ja) 1997-11-26
EP0285448A3 (en) 1990-08-29
DK483189A (da) 1989-12-04
DK483189D0 (da) 1989-10-02
US5750654A (en) 1998-05-12
FI894613A0 (fi) 1989-09-29
ES2061643T3 (es) 1994-12-16
NO178265C (no) 1996-02-21
FI894613L (fi) 1989-09-29
US6261548B1 (en) 2001-07-17
US5187077A (en) 1993-02-16
DE3888379T2 (de) 1994-07-28
JP2721123B2 (ja) 1998-03-04
WO1988007548A1 (en) 1988-10-06
SG11795G (en) 1995-06-16
NO178265B (no) 1995-11-13
CA1341581C (en) 2008-09-30

Similar Documents

Publication Publication Date Title
IL85961A (en) Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor
IL100040A0 (en) Nucleic acid amplification by two-enzyme,self-sustained sequence replication
DE3863442D1 (de) Sukroseester enthaltende, die hautpermeabilitaet vergroessernde zusammensetzungen.
HUT49592A (en) Process for producing bis/hydroxymethyl/-cyclobutyl-purines and pyrimidines, as well as pharmaceutical compositions comprising same
FI885122A7 (fi) Suun kautta nautittava kokoonpano, joka sisältää vaikuttavan aineen k äsittäviä hiukkasia
IT8921104A0 (it) Forno in particolare per la produzione di litargirio mediante calcinazione di massicot.
GB2211848B (en) Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it.
EP0262463A3 (en) Novel aureobasidium sp. microorganisms, method for preparing erythritol with the same
IL75963A0 (en) Interferon derivatives,their preparation and pharmaceutical compositions containing them
JO1406B1 (en) Chemical compounds
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
IL94081A0 (en) Soluble interferon-gamma receptors,their production and pharmaceutical compositions comprising them
ZA898101B (en) Bromonitro compound,process for the production thereof and use as blocide
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
EP0807685A3 (en) Sucrose phosphate synthase (sps), its process for preparation, its cdna and utilization of cdna to modify the expression if sps in the plant cells
ES8607015A1 (es) Preparado solido de dihidropiridina
JPS6468379A (en) Novel compound, its production and pharmaceutical composition containing the same
ATE86251T1 (de) Polycyclische verbindungen, ihre herstellung und sie enthaltende rezepturen.
IL82965A0 (en) Benzimidazoles,their production and pharmaceutical compositions containing them
IL84955A0 (en) Novel carbamoyloxylabdanes,process for the preparation thereof and pharmaceutical compositions containing them
AU1164588A (en) Nucleotide analogs, their production and use
ES8607016A1 (es) Preparado solido de nifedipina
AU1478688A (en) Novel 2beta, 16beta-diamino-androstanes
EP0300036A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON VASOPRESSIN.
ES8205218A1 (es) Un procedimiento para la preparacion de pirrolilpiperidinas utiles como agentes antidepresivo.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
EXP Patent expired